Teva Pharmaceutical Non-GAAP EPS of $0.78 beats by $0.11, revenue of $4.48B beats by $150M

Teva Pharmaceutical press release (TEVA): Q3 Non-GAAP EPS of $0.78 beats by $0.11.
Revenue of $4.48B (+4.2% Y/Y) beats by $150M.
FY25 revenue consensus of $16.88B, EPS consensus of $2.56

Outlook for 2025 Non-GAAP Results

$ billions, except EPS or as noted	January 2025	May 2025	July 2025	November 2025
Revenues*	$16.8 – $17.4	$16.8 – $17.2	$16.8 – $17.2	$16.8 – $17.0
AUSTEDO ($m)*	1,900-2,050	1,950-2,050	2,000-2,050	2,050-2,150
AJOVY ($m)*	~600	~600	630-640	630-640
UZEDY ($m)*	~160	~160	190-200	190-200
COPAXONE ($m)*	~370	~370	~370	~370
Operating Income	4.1 – 4.6	4.3 – 4.6	4.3 – 4.6	4.4 – 4.6
Adjusted EBITDA	4.5 – 5.0	4.7 – 5.0	4.7 – 5.0	4.8 – 5.0
Tax Rate	15%-18%	15%-18%	15%-18%	15%-18%
Finance Expenses	~0.9	~0.9	~0.9	~0.9
Diluted EPS ($)	2.35 – 2.65	2.45 – 2.65	2.50 – 2.65	2.55 – 2.65
Free Cash Flow**	1.6 – 1.9	1.6 – 1.9	1.6 – 1.9	1.6 – 1.9
CAPEX*	~0.5	~0.5	~0.5	~0.5
Foreign Exchange	Volatile swings in FX can negatively impact revenue and income